RFG
AVIR icon

REAP Financial Group’s Atea Pharmaceuticals AVIR Stock Holding History

REAP Financial Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$465 Hold
100
– – ﹤0.01% 522
2026
Q1 		$538 Buy
+100
New +$459 ﹤0.01% 508

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

REAP Financial Group's AVIR Position: Q2 2026 in Review

REAP Financial Group held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 100 shares worth $465. The position accounts for ﹤0.01% of the portfolio, ranked #522.

REAP Financial Group first reported a position in AVIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $538 in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • REAP Financial Group held 100 shares of Atea Pharmaceuticals worth $465 as of Q2 2026.
  • REAP Financial Group left its Atea Pharmaceuticals share count unchanged in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of REAP Financial Group's portfolio in Q2 2026, its #522 holding.
  • REAP Financial Group first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • REAP Financial Group's Atea Pharmaceuticals position peaked at $538 in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on REAP Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.